T细胞受体工程化T细胞疗法（T-cell receptor engineered T cell therapy，TCR-T）不受靶细胞表面抗原表达的限制，是一种潜在的抗肿瘤细胞免疫疗法[1]。TCR-T与嵌合抗原受体T细胞疗法（Chimeric Antigen Receptor T-Cell Immunotherapy，CAR-T）均是利用经基因修饰改造的T淋巴细胞获得肿瘤抗原特异性。数据来源：DOI: 10...
(GMP). Our RetroNectin GMP grade reagent has been used in over 68 protocols for gene therapy clinical trials, at 44 institutions worldwide. We also supply a GMP-gradeanti-CD3 antibodyfor T-cell activation as well asLymphoONE T-cell culture medium, which are optimized for use with Retro...
T-cell-based immunotherapies hold promise for the treatment of many types of cancer, with three approved products for B-cell malignancies and a large pipeline of treatments in clinical trials. However, there are several challenges to their broad implementation. These include insufficient expansion of...
The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a central focus for engaging the immune system in the fight against cancer. Basic science discoveries elucidating the molecular and cellular biology of the T cell hav
相信不久将来,也能在临床上应用。 参考文献: 1.Immune cell therapy for hepatocellular carcinoma.[J]Journal of Hematology & Oncology.2019 http://2.clinicaltrials.gov
The reasons include the lack of tumor specific antigen target on solid tumors, the uncertainty of homing ability of engineered T cells and the inhibitory immune microenvironment of tumors. In clinical trials, the targets of CAR-T cell therapy for solid tumors are mainly disialoganglioside (GD2),...
(LioCyx™) for treatment of relapsed liver cancer post-liver transplantation. The first such trial inSingaporeand for the region that uses precision T cell receptor (TCR) immune cell therapy to target Hepatitis B virus (HBV)-related liver cancer, wh...
In this context, T-cell therapy has emerged as a viable immunotherapy, using patients’ own immune cells to identify and attack cancer cells in the body. According to NIH, in 2024, around 2 million people are estimated to be diagnosed with various types of cancer in the U.S. alone and ...
Immune Therapeutics正在开发适用于各种应用的CAR-T细胞疗法。最近从新成立的公司Super-T Cell Cancer Company(“STCC”)获得了中国嵌合超级抗原受体T细胞(CAR-T)鸡尾酒疗法、免疫肿瘤学专利(正在申请中)、制造技术和治疗临床数据。 艺妙神州医药 艺妙神州正在开发用于治疗恶性肿瘤的CAR-T细胞疗法和慢病毒制造平台。由于...
A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute and...